Sort   by:  
 Page size 
ProteomicsDiscovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma
Even in the BCMA CAR-T era, multiple myeloma (MM) patients with high-risk genotypes have the poorest outcomes. We thus leveraged MMRF CoMMpass data to identify potential novel surface immunotherapeutic targets in high-risk MM. As described below, we focused on CD70, an immunotherapeutic target known...
ORGANISM(S): Homo sapiens (Human) 
2025-11-27 | PXD048492 | Pride
Car-t Cd 70 Multiple myeloma Immunotherapy 
UnknownVariants of uncertain significance in prenatal microarrays: a retrospective cohort study.
Not available
S-EPMC7856034 | biostudies-literature
UnknownGlobal cellular response to chemotherapy-induced apoptosis.
Not available
S-EPMC3808542 | biostudies-literature
UnknownGiving an Enzyme Scissors: Serotonin Derivatives as Potent Organocatalytic Switches for DNA Repair Enzyme OGG1.
Not available
S-EPMC12621200 | biostudies-literature
ProteomicsSurface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies
Alternate strategies are needed for B-cell malignancy patients relapsing after CD19-targeted immunotherapy. Here, integrated cell surface proteomics and epigenetic analysis initially revealed CD72 as an optimal target for poor-prognosis MLL-rearranged B-ALL, which we further found to be expressed wi...
ORGANISM(S): Homo sapiens (Human) 
2022-02-15 | PXD016800 | Pride
B-all Cell surface Cd72 
UnknownZinc Localization and Speciation in Rice Grain Under Variable Soil Zinc Deficiency.
Not available
S-EPMC11606578 | biostudies-literature
ProteomicsDiscovery and development of CLL-1 as a cellular immunotherapy target in juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive hematologic malignancy with myeloproliferative characteristics that affects young children and is associated with significant morbidity and mortality. Leukemia stem cells (LSCs) have been shown to drive relapse and progression in JMML and incl...
ORGANISM(S): Homo sapiens (Human) 
2025-02-03 | PXD052910 | Pride
Jmml Surfaceomics Car-t cell Immunotherapy 
ProteomicsPrimary Myeloma Proteomics using Micro IST method
The myeloma cell surface proteome (“surfaceome�) not only determines tumor interaction with the microenvironment but serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to first define surface markers most-enriched on myeloma when compared to B-c...
ORGANISM(S): Homo sapiens (Human) 
2022-05-27 | PXD032031 | Pride
Myeloma 
ProteomicsGeneration of Nomo-1 cell surfaceome database
The goal was to build a custom proteome database for cell surface proteins of Nomo-1 (AML cell line). Such custom database was meant to facilitate cross-linking (XL-MS) of cell surface proteins for this cell line using non-cleavable cross-linkers. Using such custom database helps with the computatio...
ORGANISM(S): Homo sapiens (Human) 
2023-10-04 | PXD035404 | Pride
Aml and cell surfaceome Nomo-1 
ProteomicsGenome-scale CRISPR screens identify PTGES3 as a direct modulator of AR function in advanced prostate cancer
The androgen receptor (AR) is a critical driver of prostate cancer (PCa). To study regulators of AR protein levels and oncogenic activity, we created the first live cell quantitative endogenous AR fluorescent reporters. Leveraging this novel AR reporter, we performed genome-scale CRISPRi flow cytome...
ORGANISM(S): Homo sapiens (Human) 
2025-08-08 | PXD066297 | Pride
Ar Crispr screens Ptges3 Prostate cancer 
Sort   by:  
 Page size